What dehydroepiandrosterone sulfate (DHEAS) level in postmenopausal women is concerning for adrenal cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

DHEAS Level Concerning for Adrenal Cancer in Postmenopausal Women

In postmenopausal women, markedly elevated DHEAS levels (typically >700 µg/dL or >3-fold above the upper reference limit for age and sex) should raise concern for adrenal carcinoma, though paradoxically, only 9 out of 11 adrenal cancers show elevated DHEAS while 2 may have normal levels.

Key Diagnostic Framework

The ESMO-EURACAN guidelines 1 explicitly recommend measuring DHEAS as part of the diagnostic work-up for any suspected adrenocortical carcinoma (ACC). However, the relationship between DHEAS and adrenal cancer is more nuanced than a simple cutoff:

DHEAS Patterns in Adrenal Malignancy

  • Elevated DHEAS is concerning: Research shows that 9 of 11 adrenal cancers (82%) demonstrated elevated DHEAS levels 2
  • Normal DHEAS does NOT exclude cancer: 2 of 11 adrenal cancers (18%) had normal DHEAS levels 2
  • High variability exists: DHEAS values in adrenocortical carcinomas show great variability, with mean values at 84% of age-matched controls but wide confidence intervals (33.2-212.5%) 3
  • Higher DHEAS correlates with worse prognosis: Death from ACC was more frequent in patients with high DHEAS values compared to those with low DHEAS 3

Critical Thresholds and Context

For postmenopausal women specifically:

  • Normal age-adjusted DHEAS ranges are typically 35-430 µg/dL 4
  • Values >1000 µg/dL are markedly abnormal and warrant urgent investigation 4
  • The guideline recommends measuring DHEAS alongside other sex steroids (17-OH progesterone, androstenedione, testosterone, 17-beta-oestradiol) and steroid precursors for comprehensive evaluation 1

Diagnostic Algorithm

When evaluating an adrenal mass in a postmenopausal woman:

  1. Measure complete steroid panel including DHEAS, 17-OH progesterone, androstenedione, testosterone, and 17-beta-oestradiol 1

  2. Interpret DHEAS in context:

    • Markedly elevated (>700-1000 µg/dL): High suspicion for ACC
    • Moderately elevated: Consider ACC but also benign adenomas
    • Normal or low: Does NOT exclude ACC - proceed with imaging

  3. Imaging is mandatory: CT or MRI of abdomen/pelvis/chest, or FDG-PET/CT with full-dose CT 1

  4. Look for additional red flags:

    • Tumor size >4 cm
    • Imaging features suggesting malignancy on CT
    • Clinical signs of hormone excess (Cushing's, virilization)
    • Rapid growth on serial imaging

Important Caveats

Common pitfall: Assuming elevated DHEAS is always adrenal in origin. While DHEAS is predominantly produced by the adrenal cortex, rare ovarian sex cord-stromal tumors can produce markedly elevated DHEAS (>1000 µg/dL) 4. However, in the context of an identified adrenal mass, elevated DHEAS strongly suggests adrenal pathology.

Specificity consideration: A low DHEAS level has 100% specificity for identifying benign lesions 2, meaning if DHEAS is suppressed (below age-adjusted norms), the lesion is virtually always benign. This occurs because benign cortisol-producing adenomas suppress ACTH and consequently DHEAS production.

Age adjustment is essential: DHEAS naturally declines with age in postmenopausal women, so absolute values must be compared to age- and sex-matched reference ranges 2, 3. Using age-sex corrected DHEAS ratios improves diagnostic accuracy 5.

Practical Recommendation

Any postmenopausal woman with an adrenal mass and DHEAS >700 µg/dL (or >2-3 times the upper limit of her age-adjusted reference range) requires urgent surgical evaluation for possible ACC, regardless of tumor size. The complete hormonal work-up outlined in the ESMO-EURACAN guidelines 1 should be performed, and imaging should assess for metastases to liver, bone, lungs, lymph nodes, and brain.

References

Related Questions

What does a DHEA‑S level of 37 µg/dL indicate and what management steps are recommended?
Does a low dehydroepiandrosterone sulfate (DHEA‑S) level make pituitary adrenocorticotropic hormone (ACTH)‑dependent Cushing disease less likely?
In a 47‑year‑old woman with a DHEA‑sulfate level of 199 ng/dL and a morning cortisol level of 7.6 µg/dL, what is the clinical significance and what evaluation and management steps are recommended?
What is the significance of a DHEA‑S (dehydroepiandrosterone sulfate) level of 199 ng/dL and how should it be evaluated and managed?
In a woman with hair loss and elevated dehydroepiandrosterone sulfate (DHEAS), what is the appropriate work‑up and management?
What is carbosceitine (acetyl‑L‑carnitine) and what are its recommended uses, dosing, and alternatives for peripheral neuropathy and cognitive decline?
What is the best NSAID for managing an acute gout flare?
What are the recommended indications, adult dosing regimen, contraindications, and treatment duration for carbocisteine as a mucolytic?
What medication options are recommended for a patient with schizophrenia and persistent paranoia who is currently taking paliperidone (Invega Sustenna and oral Invega) and valproic acid (Depakote)?
What are the likely causes, appropriate workup, and management for unilateral arm edema after deep‑vein thrombosis has been excluded?
Could my skin paresthesia and thumb pain be caused by carpal tunnel syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.